Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Share-based Compensation: 2019-2024

Historic Share-based Compensation for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $29.7 million.

  • C4 Therapeutics' Share-based Compensation fell 47.99% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year decrease of 16.05%. This contributed to the annual value of $29.7 million for FY2024, which is 8.91% up from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Share-based Compensation is $29.7 million, which was up 8.91% from $27.2 million recorded in FY2023.
  • C4 Therapeutics' Share-based Compensation's 5-year high stood at $30.0 million during FY2022, with a 5-year trough of $3.4 million in FY2020.
  • For the 3-year period, C4 Therapeutics' Share-based Compensation averaged around $29.0 million, with its median value being $29.7 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 526.81% in 2021, then decreased by 9.27% in 2023.
  • C4 Therapeutics' Share-based Compensation (Yearly) stood at $3.4 million in 2020, then spiked by 526.81% to $21.5 million in 2021, then skyrocketed by 39.53% to $30.0 million in 2022, then decreased by 9.27% to $27.2 million in 2023, then increased by 8.91% to $29.7 million in 2024.